

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Age-related macular degeneration (AMD); cancer; diabetic retinopathy; retinopathy of prematurity	CD160	<p>Studies in mice suggest that an anti-CD160 mAb could help treat wet AMD, retinopathies and cancer. In multiple mouse models of AMD and retinopathy, the anti-CD160 mAb decreased pathological angiogenesis compared with a control IgG1. In a mouse model of melanoma, the same mAb decreased tumor vasculature compared with a control IgG1. Next steps include evaluating various concentrations of the anti-CD160 mAb or a Fab fragment in models of ophthalmic disease and in combination with other chemotherapeutic agents in cancer models. MAT302, an antibody against CD160 receptor from MAT Biopharma S.A., is in preclinical development for solid tumors. LFB S.A. has CD160-targeting compounds in preclinical development.</p> <p>SciBX 4(16); doi:10.1038/scibx.2011.461 Published online April 21, 2011</p>	Patented; licensed to LFB Biotechnologies, a subsidiary of LFB S.A., for use in cancer; licensed to MAT Biopharma for use in ocular diseases	<p>Chabot, S. <i>et al. J. Exp. Med.</i>; published online April 11, 2011; doi:10.1084/jem.20100810</p> <p>Contact: Philippe Le Bouteiller, Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France e-mail: philippe.le-bouteiller@inserm.fr Contact: Nabila Jabrane-Ferrat, same affiliation as above e-mail: nabila.jabrane-ferrat@inserm.fr</p>